Dr. Harvey discusses how one defines chemotherapy-related febrile neutropenia.

Dr. Flowers discusses the recommended management strategies are for patients with low-risk febrile neutropenia.

Dr. Harvey discusses the risk factors for the development of febrile neutropenia in patients receiving chemotherapy.

Dr. Harvey discusses the incidence of febrile neutropenia in patients receiving chemotherapy.

Dr. Weber discusses an observational study of post-menopausal women who self-reported the use of chronic aspirin and had lower risk of melanoma versus peers who did not chronically use aspirin.

Dr. Weber explains the necessity of BRAF V600E mutation testing before a therapy regimen that includes vemurafenib.

Dr. Flaherty disusses sequencing of ipilimumab and vemurafenib as either first-line or salvage treatment.

Dr. Flaherty disusses the management of secondary malignancies that arise from vemurafenib therapy.

Dr. Flaherty disusses emerging therapies for advanced melanoma.